Regulation FD Disclosure. On September 1, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55, the Company’s investigational oral, non-opioid drug candidate being developed for inflammatory pain. The results are expected to inform dose selection for the next phase of the Company’s ongoing IND-enabling program. Subject to successful completion of the remaining…

Regulation FD Disclosure. On August 6, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. SKNY-1 is an investigational oral drug candidate being developed for obesity, which aims to preserve lean body mass while promoting weight reduction. The study evaluated SKNY-1 following repeated daily oral dosing in male and female Beagle dogs over 7 days. SKNY-1 demonstrated rapid…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 27, 2026, Mira Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ended July 24, 2026, the Company no longer meets the requirement to maintain a minimum b…

Chief Financial Officer — Alan Weichselbaum: The departure of the Chief Financial Officer without prior disagreement.

Entry into a Material Definitive Agreement. On June 3, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into an Amended and Restated Exclusive License Agreement (the “License Agreement”) with MIRALOGX LLC (“Miralogx”). Pursuant to the License Agreement, Miralogx granted the Company worldwide exclusive rights under certain intellectual property relating to the Company’s MIRA-55 and SKNY-1 development programs. The License Agreement provides the Company with worldwide rights to develop,…

Entry into a Material Definitive Agreement. On May 21, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Exclusive License Agreement, effective November 15, 2023, by and between the Company and MIRALOGX LLC. Pursuant to the Amendment, the parties expanded the Company’s exclusive licensed territory relating to Ketamir-2 from the United States, Canada, and Mexico to all countries in which patent rights exist. The Amendment also expan…

Other Events MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain. On March 23, 2026, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (the “Company”) is reporting new preclinical data evaluating the central nervous system (CNS) and behavioral effects of M…

The filing details compensation and incentive awards for the CEO, not a management change.

Other Events. On December 5, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the At The Market Offering Agreement (the “Sales Agreement”) with Rodman & Renshaw LLC, dated August 12, 2024, and amended on September 24, 2024, by an additional aggregate amount of $15,241,591.…

Unregistered Sales of Equity Securities. The information contained in

Completion of Acquisition or Disposition of Assets The information contained in

Entry into a Material Definitive Agreement On September 29, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”) pursuant to the previously announced merger agreement (the “Merger Agreement”). At closing, the Company acquired 100% of SKNY in exchange for restricted shares of the Company’s common stock, par value $0.0001 per share, issued to the shareholders of SKNY. The number of shares issued was determined based on an exchange rat…

Other Events MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ketamir-2, the Comp…

Other Events MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in animal models—and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs On July 10, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced new preclin…

Other Events MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks On July 2, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) announced preclinical results demonstrating that its proprietary drug candidate, Mira-55 , a non-psychoactive marijuana analog, delivered morphine-comparable pain relief in a validated animal model of inflammatory pain , without inducing local inflamm…

Other Events MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition On June 30, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (the “Company”) announced new animal study results from SKNY-1, a next-generation oral therapeutic the Company is under definitive agreement to acquire from SKNY Pharmaceuticals, Inc. In a zebrafish model that mimics human…

Other Events On June 17, MIRA Pharmaceuticals, Inc. (the “Company”) announced that its lead drug candidate, Ketamir-2 , currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology . The article, titled “KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG,” authored by the Company’s Chief Scientific Advisor, Dr. Itzchak Angel , will appear in the journal’s Experimental Phar…

Other Events On May 28, 2025, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) (“MIRA” or the “Company”) announced that it will participate in the BIO International Convention 2025, taking place in Boston, Massachusetts from June 16–19, 2025 . The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Separately, the Company is providing an update on the continued advancement of its clinical and precli…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. The information set forth in

Chief Financial Officer — Michelle Yanez: Ms. Yanez resigned from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 8, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff indicating that, based on the Company’s stockholders’ equity of $2,199,750 as of December 31, 2024, the Company does not currently meet the minimum stockholders’ equity requirement of $2.5 million as set forth under Nasdaq Listing Rule 5550(b)(1). Importantly, this notice…

Entry into a Material Definitive Agreement On March 19, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) entered into a binding letter of intent (the “LOI”) with SKNY Pharmaceuticals, Inc. (“SKNY”), a privately held Delaware corporation, to acquire SKNY through a stock exchange transaction (the “Acquisition”). The acquisition will bring SKNY-1, a novel oral drug candidate targeting weight loss and smoking cessation—two of the leading causes of preventable death—into MIRA’s development pipelin…

Change in Registrant’s Certifying Account. (a) Resignation of Independent Registered Public Accounting Firm By letter dated December 16, 2024, Cherry Bekaert LLP (“Cherry Bekaert”) notified the Audit Committee of the Board of Directors (the “Audit Committee”) of MIRA Pharmaceuticals, Inc’s (the “Company”) of its resignation as the Company’s independent registered public accounting firm. Cherry Bekaert’s reports on the financial statements of the Company for the years ended December 31, 2023 a…

Director — Michael Jerman: Mr. Jerman resigned due to his desire to pursue other activities.